CD274 and neoplasm: A significant increase in tumor:muscle SUVmean 1 and 4 days after therapy (following baseline imaging on day 0) with niraparib compared to the control group (2.069 ± 0.101 SUVmean vs. 2.461 ± 0.320 SUVmean, for day 1 tumor and 2.098 ± 0.276 SUVmean vs. 2.591 ± 0.224 SUVmean, for day 4; p ≤ 0.05; N = 5); however, paclitaxel and radiation only induced a slight upregulation (p > 0.05) of PD-L1 in the tumor.